SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Briefs

Inside Views

Contribute your views! Submit an Inside Views idea to info [at] ip-watch [dot] ch.

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Call For Transparency In The Trans-Pacific Partnership Negotiation

In this post, three US law professors explain a recent call by over 30 legal scholars for the US Trade Representative to increase transparency for the Trans-Pacific Partnership Agreement intellectual property chapter, and their response to Ambassador Kirk’s response that he is “strongly offended” by the suggestion that the negotiation is not adequately transparent already.





Latest Comments
  • David, thank you for the note. It appears there is... »
  • The link to the US proposal seems to be broken, an... »

  • For IPW Subscribers
    A guide to Geneva-based public health and intellectual property organisations. Read More >

    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >


    Compromise US Patent Reform Legislation Clears First Hurdle

    Published on 2 April 2009 @ 11:03 pm

    By for Intellectual Property Watch

    Sweeping patent reform legislation cleared a key United States Senate committee Thursday and is now headed for a vote on the Senate floor after compromises were reached on key sticking points in the bill.

    The measure (S 515) is the latest attempt by Senate Judiciary Committee Chairman Patrick Leahy (Democrat, Vermont) and other lawmakers to push through changes to the US patent system, and it appears to have wide support across industry sectors.

    Nevertheless, the amended version of the bill, which Leahy called a “very delicate compromise,” faces continuing strong opposition from some lawmakers and leaves several controversial issues still unresolved.

    A copy of the latest legislation is available here [pdf].

    Other amendments to the legislation are available here.

    Inequitable Conduct

    Criticism surfaced early at Thursday’s committee meeting. Senator Orrin Hatch (Republican, Utah) said he opposes the current version because it does not reward innovation and could undermine the effectiveness of the US and other patent systems. Hatch said he’s “tired” of non-innovators using inequitable conduct in dealings with the US Patent and Trademark Office (USPTO) to “walk away as infringers.”

    Under current law, a patent applicant who fails to disclose necessary information to or misleads the USPTO is denied a patent, said American Intellectual Property Law Association Executive Director Q. Todd Dickinson. Some, like Hatch, would prefer a more proportionate approach, Dickinson told Intellectual Property Watch, but the compromise measure does not address the issue.

    Inequitable conduct is “going to be new battleground” because it affects the costs of litigation and patent prosecution, said Foley & Lardner patent attorney Stephen Maebius. “Expect a push to get it in.”

    Damages

    Senator Kyl found fault with the so-called “gatekeeping” provision of the amendment that allows courts to consider whether a party’s damages request is not supported by evidence. That could force judges to consider all relevant factors before a trial even begins and drag out infringement litigation, he said.

    The problem has been that judges and juries sometimes lack sufficient information about how to calculate royalty damages, said Dickinson. Judges are reluctant to invade the jury’s territory by telling them which facts to consider and how, he said. The new language will help ensure that only cases involving substantial evidence of harm get to the jury, he said.

    The text of the damages provision differs from the bill’s last version, Maebius said. Prior language would have restricted a court’s ability to use all relevant factors to set infringement damages; the new provision makes judges gamekeepers who decide which of those factors will apply, he said.

    The compromise seems to have resolved the inability of lawmakers at least to reach political agreement to move forward, Dickinson said. The damages issue “will remain a hotspot,” although the agreement “appears to have significantly won over some key opponents,” said Maebius.

    “Best Mode”

    The compromise retains the requirement that a patent specification contain the best mode of carrying out the invention as part of the patent application, but bars best mode from being used as a way to invalidate a patent, the committee said.

    The requirement is fairly controversial because, as enforced, it is a trap for patentees, Dickinson said. The United States is the only country with such a provision, he said. Generic drug companies favour it because it helps them in lawsuits filed by large pharmaceutical companies, he said.

    Removing best mode as an invalidation tactic partly fixes the problem, Dickinson said. Moreover, it represents a step toward global harmonisation of patent rules, he said. The bill also moves the US to a “first-to-file” system, allowing it to seek to move international standardisation issues forward, he said.

    “This is tremendously important for other countries” because a first-to-file system could put the US on a par with the rest of the world as far as how patents are granted, said Maebius. It may also affect the extent to which overseas patent owners and filers can assert and defend their US patents against infringers in the US, as well as the extent to which US patents will pose a barrier in the future to products imported into the US by overseas companies, he added.

    “Meeting of Minds”

    Despite these and other issues, the panel voted 15-4 to send the act forward. Most bills with conflicting constituencies wind up with a compromise, said Sen. Dianne Feinstein (D-California), another of S 515′s co-authors. This one gives the parties 90 percent of that they want and it can tweaked on the Senate floor, she said. “We have a substantial meeting of minds” across the patent sector, she said.

    The compromise garnered praise from many opposing players, Dickinson said. AIPLA was somewhat disappointed that an amendment by Sen. Tom Coburn (R-Oklahoma) seeking to allow the USPTO to retain all fees it collects annually for a five-year, rather than one-year, period did not pass, he said. The amendment could see action on the Senate floor, however. The vote was a “great advance,” he said.

    The Business Software Alliance urged lawmakers “to resist efforts to weaken the bill,” and to pay “special attention” to several improvements, including ensuring the first-to-file regime is fair to companies which made use of technologies before they became the subject of a patent and that methods for challenging defective patents are effective.

    The Coalition for Patent Fairness, which represents a mix of technology companies and industry groups, praised the panel’s “important step forward,” but urged legislators, among other things, to ensure the USPTO has the power to gauge the validity of patents issued for technology and business methods – areas where improper patents are believed to have been most flagrant. The compromise also won applause from the Coalition for 21st Century Patent Reform, which represents manufacturers and high-tech businesses.

    The Biotechnology Industry Organisation, which has faced off against the high-tech sector on some issues, expressed appreciation for the “careful compromises” on several key issues, including damages and post-grant review. “While no compromise is ever perfect,” the panel’s action “breaks the logjam on the major issues that have held up patent reform” for several Congresses, it said.

    The Innovation Alliance, another industry group, offered “mixed reviews” for S 515, saying its post-grant review provisions will create multiple routes for contesting a patent’s validity without any meaningful protections to prevent abusive or serial attacks. That means US patent holders will “spend precious time and resources” protecting their inventions against domestic and foreign challengers with little hope of success, it said, an especially difficult situation for small inventors facing bigger and better-financed companies.

    Dugie Standeford may be reached at info@ip-watch.ch.

     

    Comments

    1. Anonymous says:

      meeting of the minds…let’s all screw the little guy

      please see http://truereform.piausa.org/ for a different/opposing view on patent reform


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.